This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues

Study Type: Interventional

Study Design: Treatment, Randomized, Single Blind (Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study

Study Primary Completion Date: July 2008

Intervention(s) in this Clinical Trial

• Drug: Bimatoprost 0.03%
  • bimatoprost 0.03%, 1 drop nightly for 3 months
• Drug: travaprost 0.004%
  • travaprost 0.004% eye drops, 1 drop nightly for 3 months
• Drug: latanoprost 0.005% eye drops
  • latanoprost 0.005%, 1 drop nightly for 3 months

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: 1
• Active Comparator: 2
• Active Comparator: 3

Primary Measures

• Hyperemia
  • Time Frame: Month 3
    Safety Issue?: No

Inclusion Criteria:

• Diagnosis of open-angle glaucoma (pseudoexfoliative or pigmentary glaucomas are allowed) or ocular hypertension

Exclusion Criteria:

• Known contraindication to latanoprost, bimatoprost or travoprost
• Uncontrolled systemic disease
• Active ocular disease other than glaucoma or ocular hypertension
• Pregnant or lactating women or women of childbearing potential NOT utilizing a medically acceptable form of birth control

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: Allergan

Overall Clinical Trial Officials and Contacts

Medical Director Study Director Allergan  

Overall Contact: Allergan Inc  clinicaltrials@allergan.com

Information obtained from ClinicalTrials.gov on October 10, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00539526

Study ID Number: MA-LUM-07-003

ClinicalTrials.gov Identifier: NCT00539526

Health Authority: United States: Institutional Review Board